550
Participants
Start Date
September 30, 2006
Primary Completion Date
September 30, 2008
Study Completion Date
September 30, 2008
Tigecycline
Treatment A: Tigecycline every 12 hours intravenous (IV) (an initial dose of 100 mg followed by 50 mg every 12 hours)
ampicillin-sulbactam
"Ampicillin-sulbactam: 1.5 g (1 g ampicillin plus 0.5 g sulbactam) to 3 g (3 g ampicillin plus 1 g sulbactam) intravenous (IV) every 6 hrs or Amoxicillin-clavulanate: 1.2 g (1000 mg amoxicillin plus 200 mg clavulanate) IV every 6 to 8 hrs.~A glycopeptide antibiotic (either vancomycin 1 g IV every 12 hrs or teicoplanin IV loading dose of 400 mg the first day followed by a maintenance dose of 200 mg daily) may be added to the aminopenicillin/betalactamase inhibitor regimen if infection with methicillin-resistant staphylococcus aureus (MRSA) is suspected or confirmed within the first 72 hrs of enrollment. If culture results fail to show a resistant organism, use of the glycopeptide may be discontinued."
Taipei
Manila
Manila
Mpumalanga
KZ-Natal
Cape Town
Bangkok
Bangkok
Bangkok
Pulau Pinang
New Hyde Park
Buffalo
Elmira
Philadelphia
Lansdale
Washington D.C.
Washington D.C.
Fort Gordon
Orlando
Vero Beach
Columbus
Lima
Detroit
Ramat Gan
Naperville
Decatur
Springfield
Topeka
Lincoln
Jonesboro
Fort Worth
Houston
Denver
Idaho Falls
Scottsdale
Chula Vista
National City
Mission Viejo
Singapore
Cambridge
Worcester
Hackensack
Neptune City
Winnipeg
Chicoutimi
Montreal
Québec
Sherbrooke
Trois-Rivières
Saskatoon
Hong Kong
Beirut
Gauteng
Daejeon
Incheon
Seoul
Seoul
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY